Privigen (immune globulin IV, 10% liquid) — J1459

The 500 mg unit-basis trap CMS HCPCS verified May 2026

J1459 is one of the few HCPCS codes that bills at 500 mg per unit. Most J-codes default to 1 mg per unit; many IVIG-aware billers default to 1 g per unit. Both shortcuts are wrong for Privigen.

Why CMS uses 500 mg per unit for IVIG

IVIG dosing is universally weight-based and runs in tens of grams per dose — orders of magnitude larger than the per-mg J-code defaults built for biologics like rituximab or pembrolizumab. CMS settled on 500 mg as the IVIG unit denominator because it produces a manageable two- to three-digit unit count for typical doses (10–300 units per infusion) and aligns with the 5 g/10 g/20 g/40 g vial sizes IVIG manufacturers ship. Most IVIG codes follow the same 500 mg pattern (J1568 Octagam, J1569 Gammagard Liquid, J1572 Flebogamma, J1599 unclassified IVIG, etc.); a few legacy codes use different bases — always verify per HCPCS descriptor.

Dosing per indication — PI / ITP / CIDP FDA Privigen label verified 2025–2026

Three FDA-approved indications, three completely different dosing regimens. The biller must match the indication ICD-10, the dose calculation, and the schedule before billing.

Worked dose & unit calculations

Infusion rate titration FDA Privigen label, infusion rate tables verified 2025–2026

IVIG must be started slow and titrated up by patient tolerance. Total infusion time per dose typically runs 2–6 hours, which drives the chair-time and 96366 add-on units.

Dose-fractionation for high-dose CIDP & ITP

High loading doses (e.g., CIDP 2 g/kg or ITP 1 g/kg) are typically split across 2–5 consecutive days to keep per-day infusion volume tolerable, especially in patients with cardiovascular or renal risk factors. Each daily infusion bills as a separate date of service with its own admin codes (96365 + 96366 × N) and its own J1459 unit count.

NDC reference — CSL Behring labeler 44206 FDA NDC Directory verified May 2026

Pad to 11 digits with a leading zero in the middle segment for CMS-1500 Box 24A. Use N4 qualifier and report units of measure (ML) and quantity drawn from the vial.

IVIG brand interchangeability Verified May 2026

IVIG products are NOT interchangeable for billing. Each brand has its own HCPCS, NDC, and ASP, and payer brand mandates differ widely. The biller's job is to match the code to the brand actually infused.

When clinical brand justification is needed

• IgA deficiency: low-IgA IVIG products (Gammagard S/D 5%, historically) preferred to reduce anaphylaxis risk. Privigen is acceptable for most IgA-deficient patients per current label, but some payers require brand-specific justification.
• Renal impairment / diabetes: sucrose-free, sorbitol-free, or low-osmolality products preferred. Privigen (proline-stabilized, hyperosmolar) carries renal precautions; some patients tolerate glycine- or maltose-stabilized products better.
• Tolerability history: if a patient had infusion reactions on one brand, switching brands sometimes resolves them. Document the prior brand, the reaction, and the rationale for switching.
• Subcutaneous transition: chronic PI patients who outgrow IV access may transition to SC IVIG (Hizentra J1559, Cuvitru, Cutaquig, Xembify, HyQvia). This is a brand and route switch — re-PA required.

Administration codes CPT verified May 2026

IVIG is not chemotherapy. Use the therapeutic IV infusion family (96365 / 96366), and expect to bill multiple 96366 add-on hours per dose because IVIG infusions run 2–6 hours.

Premedication coding

Standard Privigen premedications are acetaminophen and diphenhydramine 30–60 minutes pre-infusion. Some patients require IV corticosteroids (methylprednisolone, hydrocortisone). Premeds are billed separately with the appropriate J-code (e.g., J1200 diphenhydramine, J1100 dexamethasone) and the appropriate admin code (96372 SC/IM, 96374 IV push, or 96365/96366 if infused). Oral acetaminophen is generally not separately billable.

Modifiers — JZ, JW, and the weight-based waste calculation CMS verified May 2026

All four Privigen vial sizes (5 g, 10 g, 20 g, 40 g) are single-dose containers. Weight-based dosing rarely matches an integer vial combination — partial-vial waste is the rule.

JZ — required when no drug discarded

Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. For Privigen, JZ applies when the dose happens to match an integer combination of the 5/10/20/40 g vials — e.g., a 35 g dose = 20 + 10 + 5 g = exactly three vials, no waste. Append JZ to the J1459 line.

JW — required for documented waste of unused single-dose-vial drug

For mg/kg dosing where the calculated dose does not match an integer vial combination, partial-vial waste is the norm. CMS requires the JW modifier on a separate claim line for the discarded units (rounded per CMS rules), with the wastage documented in the medical record. Bill administered units (with JZ) and discarded units (with JW) on two separate lines, same date of service.

Apply each MAC's rounding convention. Some MACs require billing the total drawn from the vial as administered units and reporting waste only when an entire additional vial would otherwise be required. Refer to your local MAC billing article for the exact rounding rule. Small per-mg variations on a high-cost biologic translate to thousands of dollars per dose — payers audit IVIG JW claims closely.

JG / TB — 340B drug pricing

Hospitals that purchase Privigen through 340B and bill Medicare report the JG modifier (acute-care hospitals) or TB modifier (rural sole community / critical-access hospitals), per CMS guidance. Most ambulatory infusion suites and home infusion providers do not use 340B pricing; only hospital-outpatient infusion uses 340B in most networks.

Modifier 25 — same-day E/M

Append modifier 25 to the same-day E/M code if a significant, separately identifiable evaluation occurred (clinical reassessment for next-cycle decision, dose-titration encounter, etc.). Routine pre-infusion check-in is bundled.

ICD-10-CM diagnosis codes FY2026 verified May 2026

Use the most specific code supported by chart documentation. Each FDA-approved indication has a distinct code family; payer LCDs may add additional covered codes.

Site of care & place of service Verified May 2026

IVIG site-of-care steerage is among the most aggressive in specialty pharmacy. Home infusion is preferred for chronic PI and CIDP at most national payers; HOPD claims are routinely denied or downcoded.

Home infusion vs. ambulatory infusion vs. hospital outpatient — the three-way decision

• Home infusion (POS 12) — Lowest total cost. Patient receives infusion at home via a contracted home-infusion provider. Drug + nursing + supplies bundled per the home-infusion benefit (commercial: per-diem codes like S9338; Medicare Part B home infusion benefit covers select drugs). Best for stable, tolerant chronic patients with adequate venous access. UHC Optum Infusion steerage is particularly aggressive for chronic IVIG.
• Ambulatory infusion center (POS 49) — Mid-range cost. Free-standing AIC or physician-office-affiliated infusion suite. Lower facility fees than HOPD. Standard for chronic patients who are not home-infusion candidates and for new-start patients in observation period.
• Hospital outpatient (POS 19/22) — Highest total cost. OPPS / APC packaging adds substantial facility fees on top of drug ASP. Payers actively steer away from HOPD for IVIG after the first 1–3 doses. New IVIG starts where reaction risk is uncertain may be HOPD-justified; chronic stable IVIG should not be.

Claim form field mapping CSL Behring billing guide + CMS-1500 reference

CMS-1500 / 837P (physician office, AIC, home infusion; POS 11/12/49) example for a 35 g PI maintenance dose of Privigen.

Source: CSL Behring Privigen billing & coding guide; CMS-1500 instruction manual; payer policy documents (UHC, Aetna, Cigna, Anthem). Home infusion claims may use additional per-diem codes (S9338 commercial, Medicare Part B home infusion benefit codes).

Payer policy snapshot — LCD & PA criteria Reviewed May 2026

Every major payer requires PA on every IVIG start and at every reauthorization. Site-of-care UM is universal. Brand mandates vary by payer contract and refresh annually.

What to document for IVIG PA approval

• For PI: documented serum IgG levels (low for age); functional antibody response to vaccine challenge OR pre-existing antibody titers below protective; recurrent infection history with objective documentation (cultures, imaging, hospitalizations).
• For CIDP: neurologist documentation of clinical course (progressive or relapsing weakness >2 months); EMG/NCS findings consistent with demyelination; exclusion of other causes; baseline INCAT or MRC sum score.
• For ITP: platelet count (typically <30,000/µL for treatment) AND bleeding history or significant bleeding risk; failure or contraindication to corticosteroid therapy (per most payer criteria for chronic ITP).
• Site-of-care attestation: patient suitability for home infusion (vascular access, caregiver availability, prior tolerance) OR justification for AIC / HOPD (first dose, prior reaction history, complex medical needs).
• Reauthorization: documented continued benefit (IgG trough levels for PI; INCAT/MRC score improvement or stability for CIDP; platelet response for ITP).

Medicare reimbursement CMS Q2 2026 (live)

Quarterly ASP from CMS Part B Drug Pricing File. J1459 refreshes every quarter; the per-500-mg-unit rate translates to a per-gram cost via × 2.

Per-dose Medicare reimbursement at common Privigen doses

Coverage

No NCD specific to IVIG as a class. Each MAC publishes a billing & coding article covering IVIG with covered ICD-10 ranges per indication. Medicare covers Privigen for FDA-approved indications (PI, ITP, CIDP). Off-label IVIG indications (myasthenia gravis, Guillain-Barré, dermatomyositis, multifocal motor neuropathy, etc.) are covered on a MAC-by-MAC basis — verify the local LCD before billing. Bill with the indication-specific ICD-10 (see ICD-10 by indication).

Canonical code source: CMS HCPCS quarterly update file.

Patient assistance — CSL Behring AssureSupport Manufacturer site verified May 2026

• Privigen Co-pay Assistance Program (commercially-insured): Eligible commercially-insured patients may pay as little as $5 per infusion, with annual benefit caps that vary by patient and program year. Verify current cap with AssureSupport at PA stage.
• CSL Behring Patient Assistance Foundation (uninsured / underinsured): Free Privigen for qualifying uninsured patients and for underinsured patients whose insurance does not cover IVIG. Income-based eligibility.
• Single contact phone: 1-877-355-IGIV (1-877-355-4448) — CSL Behring AssureSupport / Privigen patient support hub.
• Independent foundations (Medicare patients): PAN Foundation, HealthWell Foundation, Patient Advocate Foundation, and the Assistance Fund all run open-disease IVIG funds intermittently. Verify open funds quarterly — IVIG funds are high-demand and frequently close.
• Reimbursement support: AssureSupport offers benefit verification, PA support, appeal letters, and product replacement for spoiled / damaged vials.

Common denials & how to fix them

Frequently asked questions

How many units do I bill for a Privigen dose?

Privigen (HCPCS J1459) bills at 1 unit = 500 mg. This is unusual — most J-codes use 1 mg per unit, and many IVIG-aware billers default to 1 g per unit. For Privigen specifically: a 35 g dose = 70 units (35,000 mg ÷ 500); a 50 g dose = 100 units; a 100 g loading dose for CIDP = 200 units. Defaulting to 1 mg/unit will overbill by 500x; defaulting to 1 g/unit will underbill by 2x. Both errors are major audit risks. Conversion shortcut: grams × 2 = units.

What is the Q2 2026 Medicare reimbursement for J1459 Privigen?

Q2 2026 ASP + 6% for J1459 is approximately $49.533 per 500 mg unit, which is approximately $99.07 per gram. A typical 35 g monthly PI maintenance dose = 70 units × $49.533 = $3,467.31 before sequestration. A 100 g CIDP induction = 200 units = $9,906.60. ASP refreshes quarterly — see the live snapshot above.

What are the FDA-approved indications for Privigen?

Privigen has three FDA-approved indications, each with distinct dosing: (1) primary humoral immunodeficiency (PI) in adults and children ≥3 years, dosed 200–800 mg/kg every 3–4 weeks targeting an IgG trough of 500–1,000 mg/dL; (2) chronic ITP in adults and children ≥15 years, dosed 1 g/kg/day for 1–2 days as induction; (3) CIDP in adults, with a 2 g/kg loading dose over 2–4 days followed by 1 g/kg every 3 weeks.

Why does the JW modifier apply to IVIG even though Privigen comes in single-dose vials?

All IVIG dosing is weight-based (mg/kg), so the calculated dose almost never matches an integer combination of the 5 g, 10 g, 20 g, and 40 g vial sizes. Vial-level waste is routine. CMS requires JZ on the administered units when no waste occurs, and JW on a separate line for the discarded units when an SDV is partially used. Document waste in the medical record. Small mg/kg variations on a high-cost drug like IVIG translate to thousands of dollars of waste per dose — payers audit JW closely.

Are IVIG brands interchangeable for billing purposes?

No. Each IVIG product has its own HCPCS code, NDC, and ASP (Privigen J1459, Gammagard Liquid J1569, Octagam J1568, Gamunex-C J1561, Gammaplex J1557, Bivigam J1556, etc.). Substituting brands without matching the HCPCS to the actual product administered is a denial trigger and a compliance issue. Many payers contract preferentially with specific brands — UnitedHealthcare may steer to Privigen on one PA while Aetna may require Gammagard Liquid on the next. Always document which brand was infused and bill the matching code.

What administration codes are used for Privigen?

IVIG is non-chemotherapeutic. Use 96365 (therapeutic IV infusion, initial hour) plus 96366 (each additional hour) — IVIG infusions typically run 2–6 hours per dose because the rate is titrated up gradually from 0.5 mg/kg/min, so multiple 96366 units are billed per session. Do not use the chemo admin codes 96413/96415 for IVIG. Premedications (acetaminophen, diphenhydramine, occasionally IV corticosteroids) are billed separately with their own J-codes and admin codes.

Do payers steer IVIG site of care?

Yes — site-of-care steerage on IVIG is among the most aggressive in the specialty pharmacy market. UnitedHealthcare, Aetna, Cigna, and most Blue Cross plans actively redirect IVIG infusions out of hospital outpatient (POS 19/22) into ambulatory infusion centers (POS 49) or home infusion (POS 12) where facility fees are avoided. For chronic IVIG patients (PI, CIDP), home infusion is often the preferred and required setting after the first few doses are tolerated. This is a major billing decision: HOPD claims will be denied or downcoded by the payer in many cases.

What documentation does an IVIG payer require?

IVIG prior-authorization criteria across UHC, Aetna, Cigna, and most BCBS plans require, at minimum: indication-specific ICD-10; for PI — documented serum IgG levels and functional antibody response (vaccine challenge or pre-existing antibody titers); for CIDP — neurologist documentation plus EMG/NCS findings; for ITP — platelet count and bleeding-risk assessment. Annual reauthorization requires evidence of continued benefit (IgG trough levels, INCAT/MRC scores, platelet response). Site-of-care attestation is often required as part of the PA submission.

Who is Privigen made by and what is the patient assistance contact?

Privigen is manufactured by CSL Behring. Patient support runs through CSL Behring AssureSupport. Commercially-insured patients may qualify for the Privigen Co-pay Assistance Program. Uninsured and underinsured patients may qualify for free product through the CSL Behring Patient Assistance Foundation. Single contact phone: 1-877-355-IGIV (1-877-355-4448).

Source documents

1. AAPC — HCPCS J1459 (Privigen)
   Code descriptor: "Inj ivig privigen 500 mg"
2. FDA-approved Privigen prescribing information (CSL Behring)
   Indications, dosing for PI / ITP / CIDP, infusion rate titration tables, boxed warnings (thrombosis, renal)
3. Privigen HCP resources (CSL Behring)
   Dosing & administration, billing/coding guide, reimbursement support
4. CSL Behring IGIV product portfolio
   Privigen, Hizentra (J1559 SC), and patient support program overview
5. AAAAI — Primary Immunodeficiency Practice Parameters
   PI diagnostic criteria, IVIG dose targets, IgG trough goals (500–1,000 mg/dL)
6. AAN / EAN/PNS — CIDP guidelines
   CIDP diagnostic criteria; IVIG as first-line; loading and maintenance dosing
7. ASH 2019 ITP guidelines
   IVIG indication and dosing for chronic ITP; corticosteroid step therapy context
8. UnitedHealthcare — Immune Globulin medical drug policy
   PA criteria, brand preference, site-of-care steerage (Optum Infusion home preference)
9. Aetna CPB 0206 — Intravenous Immune Globulin
   Coverage criteria by indication; on-label and select off-label coverage
10. Cigna IP0011 — Immune Globulin IV coverage policy
    PA criteria; site-of-care; reauthorization
11. CMS — Medicare Part B Drug ASP Pricing File
    Q2 2026 quarterly file (J1459 Privigen and IVIG siblings)
12. CMS — HCPCS quarterly update file
    Canonical HCPCS code source for J1459 and the IVIG family
13. CMS — JW / JZ modifier guidance
    Single-dose-container waste reporting (effective 7/1/2023)
14. CMS — Medicare home infusion therapy benefit
    Part B home infusion benefit overview (covered drugs and admin codes)
15. Immune Deficiency Foundation (IDF)
    Patient-facing PI education; IVIG vs SCIG resource pages

About this page

We maintain this page as a living reference for Privigen (J1459) and the broader IVIG class. Medicare ASP pricing for J1459 (and the IVIG sibling codes) is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a manufacturer guide, FDA label, or major payer policy changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• May 2, 2026 — Initial publication of the Privigen (J1459) reference. ASP data: Q2 2026. Payer policies verified: UnitedHealthcare immune globulin medical drug policy, Aetna CPB 0206, Cigna IP0011 IVIG, BCBS plan-by-plan. CSL Behring AssureSupport patient assistance contact verified. Site-of-care steerage (UHC Optum Infusion, Aetna home/AIC, Cigna Accredo) documented.

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File for J1459. Payer policies are read directly from each payer's published medical policy documents. We do not paraphrase from billing-software vendor blogs. When manufacturer guidance and payer policy conflict (as with brand preference — CSL would prefer Privigen on every PA, but payer contracts rotate brands), we surface the conflict rather than picking a side.